PITTSBURGH, June 3, 2024
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a
global healthcare company, today announced that as part of its
ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D.,
has been appointed as the newest member of its Board of Directors.
Dr. Vivaldi will serve as a member of the recently reestablished
Science and Technology Committee of the Board of Directors.
"We are pleased to welcome Dr. Vivaldi to our Board of
Directors," said Melina Higgins,
Chair of the Board, Viatris. "We believe his proven expertise and
long track record of success will enhance the efforts of the Board
across a range of areas, in particular with regards to our Science
and Technology Committee. We expect his insights to be greatly
beneficial to the Company's growth strategy as we further invest in
our pipeline by adding highly innovative products with meaningful
patient impact."
Dr. Vivaldi is the former President and Chief Executive Officer
of Sigilon Therapeutics, Inc., a diabetes cell therapy company,
where he also served as a member of the company's board of
directors from 2018 until its acquisition by Eli Lilly and Company
in 2023. Prior to joining Sigilon, Dr. Vivaldi served as Executive
Vice President and Chief Global Therapeutics Officer at Bioverativ
Inc., Chief Commercial Officer at Spark Therapeutics, and as Chief
Executive Officer of Minerva Neurosciences, Inc. Earlier in his
career, Dr. Vivaldi led Genzyme Corporation's rare disease business
as President of both the rare disease business and the renal &
endocrine group and served as Senior Vice President and General
Manager of Genzyme's Latin America Group. During his tenure at
Genzyme, he led the successful approval of more than 15 orphan
products in more than 20 countries.
Dr. Vivaldi received a medical degree from the Universidade do
Rio de Janeiro after which he
completed a residency in endocrinology at the Universidade do
Estado do Rio de Janeiro and a
fellowship at Mount Sinai Hospital Center in New York in the department of genetics,
focusing on Gaucher disease. In addition, Dr. Vivaldi holds an
M.B.A. from COPPEAD, Universidade Federal do Rio de Janeiro.
"We are thrilled to have Dr. Vivaldi as a member of our Board,"
said Scott A. Smith, Chief Executive
Officer, Viatris. "He is an industry leader with an excellent track
record of leading the successful approval and launch of numerous
innovative medicines for rare and orphan diseases and positioning
global franchises for growth. I look forward to his contributions
as we continue to lead the company into what we believe is an
exciting future ahead."
Dr. Vivaldi commented, "I am excited to join Viatris, a company
with the scale and scope to reach more than 1 billion patients each
year and a clear strategy to increase the level of innovation
across its pipeline as it seeks to further expand the patient
impact and value the Company can deliver. Viatris' bold vision of
providing access to high-quality medicines to patients globally,
regardless of geography, deeply resonates with me as my entire
career has been focused on pursuing this same goal. It is an honor
to join the Viatris Board and I look forward to working alongside
my fellow Directors and with the Executive Leadership Team as the
company continues to build upon its very strong foundation."
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company
uniquely positioned to bridge the traditional divide between
generics and brands, combining the best of both to more
holistically address healthcare needs globally. With a mission to
empower people worldwide to live healthier at every stage of life,
we provide access at scale, currently supplying high-quality
medicines to approximately 1 billion patients around the world
annually and touching all of life's moments, from birth to the end
of life, acute conditions to chronic diseases. With our
exceptionally extensive and diverse portfolio of medicines, a
one-of-a-kind global supply chain designed to reach more people
when and where they need them, and the scientific expertise to
address some of the world's most enduring health challenges, access
takes on deep meaning at Viatris. We are headquartered in the U.S.,
with global centers in Pittsburgh,
Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
LinkedIn, Instagram, YouTube and X (formerly
Twitter).
Forward Looking Statements
This press release includes
statements that constitute "forward-looking statements." These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such forward
looking statements may include statements regarding the company's
growth strategy as we further invest in our pipeline by adding
highly innovative products with meaningful patient impact, and
leading the company into what we believe is an exciting future
ahead. Because forward-looking statements inherently involve risks
and uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: actions and decisions of healthcare and
pharmaceutical regulators; changes in healthcare and pharmaceutical
laws and regulations in the U.S. and abroad; any regulatory, legal
or other impediments to Viatris' ability to bring new products to
market, including but not limited to "at-risk" launches; Viatris'
or its partners' ability to develop, manufacture, and commercialize
products; the scope, timing and outcome of any ongoing legal
proceedings, and the impact of any such proceedings; the
possibility that Viatris may be unable to realize the intended
benefits of, or achieve the intended goals or outlooks with respect
to, its strategic initiatives; the possibility that Viatris may be
unable to achieve intended or expected benefits, goals, outlooks,
synergies, growth opportunities and operating efficiencies in
connection with divestitures, acquisitions, other transactions or
restructuring programs, within the expected timeframes or at all;
goodwill or impairment charges or other losses related to the
divestiture or sale of businesses or assets; Viatris' failure to
achieve expected or targeted future financial and operating
performance and results; the potential impact of public health
outbreaks, epidemics and pandemics; any significant breach of data
security or data privacy or disruptions to our information
technology systems; risks associated with international operations;
the ability to protect intellectual property and preserve
intellectual property rights; changes in third-party relationships;
the effect of any changes in Viatris' or its partners' customer and
supplier relationships and customer purchasing patterns; the
impacts of competition; changes in the economic and financial
conditions of Viatris or its partners; uncertainties and matters
beyond the control of management, including general economic
conditions, inflation and exchange rates; failure to execute stock
repurchases consistent with current expectations; stock price
volatility; and the other risks described in Viatris' filings with
the Securities and Exchange Commission (SEC). Viatris routinely
uses its website as a means of disclosing material information to
the public in a broad, non-exclusionary manner for purposes of the
SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no
obligation to update these statements for revisions or changes
after the date of this press release other than as required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viatris-appoints-rogerio-vivaldi-coelho-md-to-board-of-directors-302161288.html
SOURCE Viatris Inc.
